Amphastar Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AMPHASTAR PHARMS INC, and when can generic versions of AMPHASTAR PHARMS INC drugs launch?
AMPHASTAR PHARMS INC has fourteen approved drugs.
There are three US patents protecting AMPHASTAR PHARMS INC drugs.
There are seventy-five patent family members on AMPHASTAR PHARMS INC drugs in forty-one countries and seventy-two supplementary protection certificates in nine countries.
Summary for Amphastar Pharms Inc
International Patents: | 75 |
US Patents: | 3 |
Tradenames: | 13 |
Ingredients: | 12 |
NDAs: | 14 |
Drugs and US Patents for Amphastar Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 209933-001 | Sep 25, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | RX | Yes | Yes | 10,213,487 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Amphastar Pharms Inc | SUCCINYLCHOLINE CHLORIDE | succinylcholine chloride | INJECTABLE;INJECTION | 213432-001 | Jun 8, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Amphastar Pharms Inc | CORTROSYN | cosyntropin | INJECTABLE;INJECTION | 016750-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Amphastar Pharms Inc | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 209933-002 | Sep 25, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Amphastar Pharms Inc | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 209832-001 | Dec 18, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Amphastar Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | 6,938,798 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AMPHASTAR PHARMS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
International Patents for Amphastar Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 3258919 | ⤷ Try a Trial |
Japan | 2018507852 | ⤷ Try a Trial |
Ecuador | SP17053843 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2020204991 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017220879 | ⤷ Try a Trial |
Finland | 3258919 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Amphastar Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0268956 | 1999C0030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
1948158 | 16C0018 | France | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN,SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN,C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL) PROPIONATE-(S)-3'-METHYL-2'-(PENTANOY(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE)DE TRISODIUM HEMIPENTAHYDRATE; REGISTRATION NO/DATE: EU/1/15/1058 20151123 |
1685839 | 92292 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
2203431 | 92666 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
0290047 | SPC/GB97/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
2932970 | 1890039-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.